- Reports Q2 (Jun) earnings of $0.55 per share, $0.10 better than the S&P Capital IQ Consensus of $0.45; revenues rose 9.4% year/year to $358.9 mln vs the $360.46 mln S&P Capital IQ Consensus.
- Co issues upside guidance for Q3, sees Q3 revs of $295-305 mln vs. $278.33 mln S&P Capital IQ Consensus.
- Co issues upside guidance for FY19, sees FY19 revs of +9-11% yr/yr to ~$1.19-1.21 bln vs. $1.17 bln S&P Capital IQ Consensus, and compared to prior guidance of 5% to 7%
- Reports Q2 (Jun) earnings of $1.54 per share, excluding non-recurring items, $0.03 better than the S&P Capital IQ Consensus of $1.51; revenues rose 6.2% year/year to $385.56 mln vs the $382.81 mln S&P Capital IQ Consensus.
- "We are only scratching the surface of what is possible in key growth areas such as ESG, factors, fixed income, wealth management, index derivatives and private assets. We see enormous growth opportunities in front of us, and our strong performance in the first half of 2019 amid a rapidly transforming industry is a testament to the value we bring to the global investment community.

- Reports Q2 (Jun) earnings of $0.46 per share, $0.07 worse than the S&P Capital IQ Consensus of $0.53; revenues fell 3.0% year/year to $2.58 bln vs the $2.84 bln S&P Capital IQ Consensus.
- Earnings reflect higher electric and natural gas margins primarily due to non-fuel riders and regulatory rate outcomes, more than offset by 5 cents per share of unfavorable weather, increased depreciation, interest and operating and maintenance expenses.
- Co reaffirms guidance for FY19, sees EPS of $2.55-2.65 vs. $2.62 S&P Capital IQ Consensu
- Reports Q2 (Jun) earnings of $4.30 per share, $0.56 better than the S&P Capital IQ Consensus of $3.74; revenues rose 198.9% year/year to $34.38 bln vs the $33.27 bln S&P Capital IQ Consensus.
- Co issues upside guidance for FY19, sees EPS of $16.60-16.90 vs. $16.53 S&P Capital IQ Consensus; sees FY19 revs of $136-137 bln vs. $133.64 bln S&P Capital IQ Consensus.
- 2020 OUTLOOK
- Health Services' projected 2020 retention rate for the 2019 selling season for pharmacy services is now in the range of 97% to 98%, an increase of 50 bps from the midpoint of our previous expectations.
- Health Services' adjusted pharmacy scripts 9 are expected to grow 25 to 35 million scripts organically in 2020
After Hours Summary: SPWR +20%, CRUS +7%, PS -29%, WLL -17%, FIT -14%, QCOM -5%, PRU -4% among notable earnings/guidance moversAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: SPWR +19.8%, BOOT +13.5%, FIVN +13.4%, RUBI +9.1%, ALSN +8.1%, CRUS +7%, ACAD +6.6%, TIVO +5.5%, WTI +5.3% (light volume), LPI +5.1%, AYX +3.8%, KGC +3.2%, CTSH +2.9%, WDC +2.6%, MCK +2.2%
Companies trading higher in after hours in reaction to news: RES +9.1% (to join S&P SmallCap 600), NVAX +3.5% (ticking higher; Novavax and Catalent's Paragon unit close strategic partnership; Paragon has now purchased ~$18 million assets from Novavax), ADPT +2.4% (ticking higher-receives New York CLEP approval for clonoSEQ Assay to detect and monitor MRD in patients with certain blood cancers)
First Solar (FSLR) results lifting solar names: CSIQ +2.1%, etf- TAN +1.5%, JKS +0.9%, FSLR +0.5%After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: PS -29.3%, WLL -16.6%, FIT -13.8%, CMPR -12.4%, CXO -9.7%, NLS -6.7%, QCOM -4.8%, TTEK -4.1%, PRU -3.8%, TRMB -3.5%, PK -3.3%, CAKE -2.5% (also to acquire Fox Restaurant Concepts and remaining interest in North Itali), LRCX -2%, TWLO -1.9%, AM -1.3%, DXCM -1.2%
Companies trading lower in after hours in reaction to news: BYND -3.8% (ongoing volatility), GPN -2.3% (following TSS earnings), KLAC -1.4% / AMAT -0.7% (following LRCX earnings/guidance)

